SuperworthTeladoc Health TDOC
- Market cap
- $1.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.5B
- −2% on a year ago
- Net margin
- −7.1%
- Free cash flow yield
- 22.0%
Teladoc Health trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.5B over the last twelve months, down 2% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $660.2M+8% | $660.5M+4% | $646.1M+3% | $642.4M−2% | $640.5M−3% | $640.5M−3% | $629.4M−3% | $631.9M−2% | $626.4M−2% | $642.3M+0% | $613.8M−3% | $606.9M−4% | |
| Cost of revenue | $186M+0% | $193.4M+2% | $194.5M+2% | $188.1M−1% | $179.7M−3% | $188.9M−2% | $196.8M+1% | $190.5M+1% | $187.2M+4% | $197M+4% | $197.5M+0% | $190.8M+0% |
| Gross profit | $474.3M+11% | $467.1M+4% | $451.6M+3% | $454.4M−2% | $460.8M−3% | $451.6M−3% | $432.5M−4% | $441.4M−3% | $439.3M−5% | $445.2M−1% | $416.3M−4% | $416.1M−6% |
| R&D | $84.3M−0% | $89.9M+8% | $81.4M−6% | $76.8M−12% | $72.4M−14% | $76.8M−15% | $70M−14% | $68.8M−10% | $67.6M−7% | $71.6M−7% | $67.9M−3% | $62.9M−9% |
| SG&A | $168M+1% | $162.4M−8% | $166.1M−2% | $160M−11% | $161.7M−4% | $152.7M−6% | $161.5M−3% | $158.1M−1% | $150.8M−7% | $156.1M+2% | $153.4M−5% | $153.4M−3% |
| −$64.7M−10% | −$35.1M−99% | −$87.1M+13% | −$841.1M+1074% | −$44.4M−31% | −$48.2M+37% | −$120.6M+38% | −$54.4M−94% | −$52M+17% | −$36M−25% | −$61.8M−49% | −$37.1M−32% | |
| Interest expense | $5.6M−8% | $5.5M+21% | $5.6M+7% | $5.6M−3% | $5.7M+0% | $6.8M+24% | $5.8M+2% | $4.5M−21% | $4.5M−20% | $5M−28% | $5.4M−7% | $5.1M+14% |
| Pre-tax income | −$59.6M−20% | −$25.4M−99% | −$79.2M+16% | −$833.8M+1161% | −$32.5M−45% | −$48.2M+90% | −$111.3M+41% | −$40.4M−95% | −$50.2M+55% | −$33.6M−30% | −$60.8M−45% | −$37.9M−6% |
| −$2.5M+112% | $3.5M | $2.7M+295% | $3.9M | $780K | $238K−93% | −$18.3M | −$7.8M | −$715K | −$8.5M | $3M | $997K | |
| Net income | −$57.1M−22% | −$28.9M−99% | −$81.9M+18% | −$837.7M+1185% | −$33.3M−42% | −$48.4M+68% | −$93M+14% | −$32.7M−96% | −$49.5M+49% | −$25.1M−48% | −$63.8M−31% | −$38.9M+19% |
| −$0.35−22% | −$0.17−99% | −$0.49+17% | −$4.92+1130% | −$0.19−46% | −$0.28+65% | −$0.53+8% | −$0.19−96% | −$0.28+47% | −$0.14−50% | −$0.36−32% | −$0.21+11% | |
| 165.1M+2% | 166.1M+2% | 167.7M+3% | 170.2M+4% | 171.5M+4% | 172.8M+4% | 174.2M+4% | 175.9M+3% | 176.9M+3% | 177.8M+3% | 179.1M+3% | 181M+3% |
Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them. 29 periods, Q2 FY19 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
SG&A: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Income tax: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Teladoc Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TDOCTeladoc Health | $1.2B | n/m | n/a | 0.5× | −2% | −7.1% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| SBCSBC Medical | $543M | 11.2× | 8.2× | 3.1× | −7% | 28.0% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| Peer median | $1.7B | 26.9× | 37.2× | 1.4× | +8% | 5.0% |
More on Teladoc Health
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 199Healthcare stocks with the highest free cash flow yield
- #1of 32Hospital and care facility stocks with the highest free cash flow yield
- #7of 45Hospital and care facility stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .